CH-275
CH-275 is a synthetic compound that has been studied for its potential pharmacological effects. It is primarily known for its role as a selective agonist of the adenosine receptor subtypes, particularly the A1 receptor. This compound has been utilized in research to better understand the physiological and pathological roles of adenosine receptors in various tissues.
Pharmacology[edit | edit source]
CH-275 acts as a selective agonist for the A1 adenosine receptor, which is a G protein-coupled receptor (GPCR) involved in numerous physiological processes. Activation of the A1 receptor by CH-275 can lead to a variety of effects, including modulation of neurotransmitter release, regulation of cardiac function, and influence on renal blood flow.
Mechanism of Action[edit | edit source]
The A1 adenosine receptor, when activated by CH-275, inhibits adenylate cyclase activity, leading to a decrease in intracellular cAMP levels. This results in the modulation of ion channels and other downstream signaling pathways, ultimately affecting cellular responses such as decreased heart rate and reduced neurotransmitter release.
Therapeutic Potential[edit | edit source]
Research into CH-275 has suggested potential therapeutic applications in conditions such as cardiac arrhythmias, ischemia, and neuroprotection. By selectively targeting the A1 receptor, CH-275 may offer benefits in reducing cardiac workload and protecting tissues from ischemic damage.
Research and Development[edit | edit source]
CH-275 has been primarily used in preclinical studies to explore the role of adenosine receptors in various biological systems. Its selectivity for the A1 receptor makes it a valuable tool in dissecting the specific contributions of this receptor subtype in physiological and pathological contexts.
Safety and Toxicology[edit | edit source]
As with many research compounds, the safety profile of CH-275 in humans is not well-established. Studies in animal models have been conducted to assess its pharmacokinetics and potential toxicological effects, but further research is needed to fully understand its safety in clinical settings.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
